CN1181061C - 2,4,5-trisubstituted imidazole compounds and its preparing process and pharmaceutical use - Google Patents

2,4,5-trisubstituted imidazole compounds and its preparing process and pharmaceutical use Download PDF

Info

Publication number
CN1181061C
CN1181061C CNB021497524A CN02149752A CN1181061C CN 1181061 C CN1181061 C CN 1181061C CN B021497524 A CNB021497524 A CN B021497524A CN 02149752 A CN02149752 A CN 02149752A CN 1181061 C CN1181061 C CN 1181061C
Authority
CN
China
Prior art keywords
compound
formula
mdr
phenyl
diketone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB021497524A
Other languages
Chinese (zh)
Other versions
CN1425653A (en
Inventor
符立梧
阮继武
古练权
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Yat Sen University
Original Assignee
Sun Yat Sen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Yat Sen University filed Critical Sun Yat Sen University
Priority to CNB021497524A priority Critical patent/CN1181061C/en
Publication of CN1425653A publication Critical patent/CN1425653A/en
Application granted granted Critical
Publication of CN1181061C publication Critical patent/CN1181061C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to a 2, 4, 5-trisubstituted imidazole compound shown in a formula I, a preparation method of the compound and an application of the compound for preparing medicines used for reversing multi-drug resistance of mediate tumor cells of P-glucoprotein (P-gp), multi-drug resistance-associated protein (MRP), lung multi-drug resistance-associated protein and other membrane transport protein (ABC) families, and for recovering the sensitivity of MDR tumor cells to anti-cancer medicines. In the formula I, R#-[1], R#-[2]and R#-[3]are defined as the specification.

Description

2,4,5-tri-substituted imidazoles and preparation method thereof and pharmaceutical applications
Technical field
The present invention relates to 2,4,5-tri-substituted imidazoles and preparation method thereof, and this compounds is used for the multidrug resistance (MDR) of reversing tumor cell in preparation, recovers the purposes of tumour cell to the medicine of cancer therapy drug susceptibility.
Technical background
Tumour is prestige human life of association and healthy principal disease, is No. second human killer.The main means of treatment tumour are operation, radiation and chemotherapy.Operation, radiotherapy all can not clear all exactly tumour cell and the recurrence easily of treatment back are the locality treatment.And chemotherapy is a systemic treatment, but the major cause of chemotherapy failure is: one, dose limitation toxic side effect.Because cancer therapy drug is lower to the selectivity of tumour cell, when killing tumour cell, normal histocyte is also had lethal effect, has limited the application dose of cancer therapy drug.Its two, tumour cell has produced resistance to cancer therapy drug, especially multidrug resistance (Multidrug resistance, MDR).MDR is the major cause of chemotherapy of tumors failure, also is the difficult problem that solution is badly in need of in the chemotherapy of tumors field.
MDR is divided into geneogenous, promptly contacts before the chemotherapeutics just to exist, as intestinal cancer, kidney, liver cancer etc.: and acquisition, promptly contact medicine to induce, as leukemia, myelomatosis, lymphoma, lung cancer etc.The reason that MDR forms is very complicated, and relevant with epicyte protein has: P-glycoprotein (P-gp.P170), MRP (MRP), lung cancer MRP (LRP); Also, relevant as topoisomerase II, PKC etc. with tenuigenin, the relevant many factors of nucleus.But the MDR by P-gp mediation is called as typical MDR, and this also is the reason of most important clinically, kinds of tumor chemotherapy failure.In fact, P-gp is a kind of cancer therapy drug efflux pump of energy dependence, makes drug accumulation minimizing in the cell, therefore, has produced resistance.Its resistance spectrum is mainly and derives from natural cancer therapy drug, as anthracene nucleus class, vinca, podophillotoxines, taxanes etc.
In theory, overcoming multidrug resistance has two kinds of approach, one, and exploitation does not have drug-fast new anti-cancer drug thing to the MDR cell.Its two, seek MDR reversal agents and share with cancer therapy drug, recovery MDR cell is to the susceptibility of cancer therapy drug.This is a kind of promising method.P-gp is not that the drug-resistant tumor cell is distinctive in fact, expresses MDR at normal tissue cell such as liver, kidney, intestines etc. yet, and its physiological function is relevant with secretion with detoxifcation.Recently, have the people to remove mdr1a and the mdr1b of mouse simultaneously, mouse still can healthy survive as a result, and this prompting P-gp is not the necessary composition of basic physiological function.This shows that it is acceptable that the P-gp inhibitor is applied in the body, and it is feasible that the exploitation MDR reversal agents is used for clinical as medicine.The inhibitor of existing report P-gp and cancer therapy drug share and can suppress the mdr1 expression of gene and reduce the drug-fast rate that induces of Zorubicin.This shows that before resistance appears in tumour cell reversal agent and cancer therapy drug share also help.
In order to seek the reversal agent of MDR, people have carried out extensive studies.Nineteen eighty-two Tsuro etc. find calcium channel blocker, and the effect as Verapamil (VRP) has external reversion MDR indicates that first-generation MDR reversal agents produces.But because its cardiovascular toxic side effect, make it not reach Plasma Concentration and can not be used for reversion MDR in the body with reversion MDR effect.Similar research has inhibitor, Ciclosporin A and the diversified lipophilic cation compound etc. of calmodulin.
With the exploitation of Switzerland Sadonz company is the MDR reversal agents appearance of representative with PSC833, indicates that s-generation MDR reversal agents produces.S-generation MDR reversal agents often reverses active strong than first-generation reversal agent, toxicity is low, also has the reversion MDR effect in the body.But be used for the clinical brilliant prospect that do not show.This is because this compounds is the substrate of P-gp, affect the blood medicine kinetics of cancer therapy drug, but for the side effect that reduces cancer therapy drug to tolerance degree, this class reversal agent and anticarcinogen share, dosage (Chang Weizheng usual amounts 70%) to conventional amount used that must the minimizing cancer therapy drug.This is also just restricting the anticancer effect of cancer therapy drug itself, and the cell of possible part P-gp feminine gender also can tolerate this lower concentration cancer therapy drug.When share, must reduce the taxol dosage to 70% of conventional amount used as PSC833, VX-710 and taxol.Similar report has tamoxifen and Zorubicin to share, and also must reduce the dosage of Zorubicin.Therefore, the exploitation of s-generation MDR reversal agents is worth and also is restricted.
The MDR reversal agents of a new generation except must be efficient, the low toxicity, should consider that also they are to cancer therapy drug absorption, metabolism and excretory influence.Recently, there have report compound OC144-093 to have a strong reverse to be active and may not be the substrate of P-pg, and its mechanism of action mainly is to combine with P-gp, thereby influences " Teat pipette " function of P-gp.This compound does not influence the pharmacokinetics of cancer therapy drug, and therefore, when reversal agent and this compounds share, anticarcinogen did not need decrement.This indicates the appearance of third generation MDR reversal agents.
Summary of the invention
The purpose of this invention is to provide a class new 2,4,5-tri-substituted imidazoles and preparation method thereof, and this compounds is used for the multidrug resistance (MDR) of reversing tumor cell in preparation, recovers the purposes of tumour cell to the medicine of cancer therapy drug susceptibility.
Of the present invention 2,4, the chemical structural formula of 5-tri-substituted imidazoles is as (to be designated hereinafter simply as formula I compound) shown in the following formula I:
Figure C0214975200051
Formula I
R among the formula I 1, R 2, R 3The group of representative is as described in the and the following:
(1) R 1Be selected from one of the following stated group:
1. the phenyl of Qu Daiing, said here substituting group is:
C 1-6Alkyl, C 1-6Alkoxyl group, C 1-6Alkylamino, trans-CH=CHR 4, trans-CH=CHCH 2OR 5, trans-CH=CHCO 2R 5, trans-CH=CHCH 2NR 5R 6Or trans-CH=CHCONR 5R 6
Above-mentioned trans-CH=CHR 4In R 4Be pyridyl, thienyl, oxazolyl or thiazolyl; Trans-CH=CHCH 2OR 5, trans-CH=CHCO 2R 5, trans-CH=CHCH 2NR 5R 6And trans-CH=CHCONR 5R 6In R 5, R 6Can be identical, also can be different, be H, C 1-6Alkyl, C 3-6Cycloalkyl or phenyl, NR wherein 5R 6Also comprise N-pyrryl, N-piperidyl or N-morphine quinoline base;
2. the pyridyl of Qu Daiing, furyl, thienyl, indyl Huo oxazolyl, said here substituting group is:
Halogen, C 1-6Alkyl, C 1-6Alkoxyl group, C 1-6Alkylthio, C 1-6Alkylamino, C 1-6Alkoxy C 1-6Alkyl, C 1-6Alkylthio C 1-6Alkyl or C 1-6Alkylamino C 1-6Alkyl;
(2) R 2, R 3Can be identical, also can be different, be phenyl or the pyridyl that replaces.Here said substituting group is:
Halogen, C 1-6Alkyl, C 1-6Alkoxyl group, C 1-6Alkylthio, C 1-6Alkylamino, C 1-6Dialkyl amido, N-pyrryl, N-piperidyl or N-morphine quinoline base.
Shown in the formula I of the present invention 2,4, the 5-tri-substituted imidazoles can make by corresponding diketone and aldehyde reaction.Its building-up process is suc as formula shown in the II:
Formula II
Concrete preparation method's step is:
1 normal diketone and 1～1.5 normal aldehyde are dissolved in the Glacial acetic acid, are heated to 140 ± 5 ℃; In addition with 3～5 normal NH 4OAc places Glacial acetic acid, also is heated to 140 ± 5 ℃; After the solid for the treatment of both sides all dissolves fully, with NH 4The glacial acetic acid solution of OAc adds in the glacial acetic acid solution of diketone and aldehyde, 140 ± 5 ℃ of reaction 1～2h; Steam solvent, promptly obtain corresponding polyaryl substituted imidazole compound through column chromatographic isolation and purification then.
Diketone used in the invention described above formula I compounds process for production thereof can make by building-up process shown in the following formula III:
Figure C0214975200062
Formula III
Concrete preparation method's step is:
With 1 normal 4,4 '-difluoro benzil is dissolved among the DMSO, adds 2～3 equivalents and replaces amine, at 70～90 ℃ of following reacting by heating 10～15h of oil bath, steams solvent, and column chromatographic isolation and purification obtains corresponding diketone.
Used aldehyde can be by making as shown in the formula building-up process shown in IV, formula V or the formula VI or additive method in the invention described above formula I compounds process for production thereof:
Formula IV
Formula V
Figure C0214975200073
Formula VI
Concrete preparation method's step is:
(1) preparation of substituted benzaldehyde:
1. with the Pd (OAc) of catalytic amount 2And PPh 3The DMF that places adds p-bromobenzaldehyde and methyl acrylate, 100 ℃ of reaction 10～15h, and column chromatographic isolation and purification obtains 1-(right-the formyl radical phenyl)-anti--methyl acrylate;
2. 1-(right-the formyl radical phenyl)-anti--methyl acrylate is dissolved in the benzene, adds 2～3 equivalent ethylene glycol, load onto water trap, back flow reaction 2～4h obtains 1-(right-ethylene glycol contract formyl radical phenyl)-anti--methyl acrylate;
3. at room temperature, to anhydrous diethyl ether and LiAlH 4Slowly splash into the anhydrous ether solution that is dissolved with 1-(right-ethylene glycol contract formyl radical phenyl)-anti--methyl acrylate in the suspension that blendes together; drip off back restir 60 minutes; the NaOH aqueous solution that adds 1M; stir after 20 minutes; standing demix, water layer are used extracted with diethyl ether again, the combined ether layer; wash with saturated NaCl solution, use anhydrous Na 2SO 4Drying steams solvent after column chromatographic isolation and purification obtains 1-(right-ethylene glycol contract formyl radical phenyl)-anti--vinylcarbinol;
4. 1-(right-ethylene glycol contract formyl radical phenyl)-anti--vinylcarbinol is dissolved among the DCM, adds Ph 3P, CCl 4, behind the room temperature reaction 3h, add saturated NaHCO 3The aqueous solution stirred 20 minutes, and standing demix, water layer with the DCM extraction, merge organic layer again, wash with the saturated NaCl aqueous solution, use anhydrous Na 2SO 4Drying steams solvent after column chromatographic isolation and purification obtains right-ethylene glycol formyl radical phenyl-anti--chlorallylene that contracts;
5. will be 4. the right-ethylene glycol of the gained formyl radical phenyl-anti--chlorallylene that contracts then use the dilute acid hydrolysis acetal with reactions such as various amine, alcohol, mercaptan, then can obtain various aldehyde;
6. will be 2. use the dilute acid hydrolysis acetal behind the 1-of gained (right-ethylene glycol contract formyl radical phenyl)-anti--methyl acrylate and the various amine exchange reaction, then can obtain various aldehyde.
(2) preparation of 3-indolecarboxaldehyde compounds:
Bathe under fully cooling and the stirring 1 normal POCl at cryosel 3Splash among the 4 normal DMF, obtain pink solution, maintain the temperature at and splash into the solution that 0.8～1 equivalent Benzazole compounds is dissolved in a small amount of DMF below 10 ℃, be warming up to 35 ℃ of left and right sides stirring reactions 1～2 hour, under the ice bath cooling, slowly add trash ice, stir.In a beaker, add a large amount of trash ices, above-mentioned solution poured into, stir down the NaOH cold soln is slowly added, after adding solid is leached, after air-dry various 3-indolecarboxaldehyde compounds.
(3) preparation of (right-formyl radical) styryl pyridine compound:
With terephthalaldehyde, picoline compounds, aceticanhydride reflux together 3～5 hours, being neutralized to pH with 1MNaOH solution was 8～9, uses CH 2Cl 2Extraction merges organic layer, uses anhydrous Na 2SO 4Drying steams solvent after column chromatographic isolation and purification obtains (right-formyl radical) styryl pyridine compound.
Aforesaid method of the present invention institute synthetic compound structure MS, 1Conclusive evidences such as H-NMR, IR and ultimate analysis.
The present invention is by the reversal experiment of inside and outside kinds of tumors drug-resistant cell strain, proved of the present invention 2,4, the 5-tri-substituted imidazoles is compound 12 (FG020326 especially, embodiment 12), compound 16 (FG020327, embodiment 16) and compound 17 (FG020718, embodiment 17) have extremely strong reversing tumor cell MDR effect.
Studies show that with two pairs of multidrug resistance cell strains and corresponding sensitive strain KBv200 thereof and KB (cancer at the bottom of the oral cavity), MCF-7/adr and MCF-7 (mammary cancer), 2,4, the 5-tri-substituted imidazoles all has significant reverse effect to MDR cell KBv200 and MCF-7/adr, FG020326 wherein, FG020327 and FG020718 are under the acellular malicious concentration of 5 μ mol/L, can reverse the resistance of KBv200 and MCF-7/adr fully, be better than traditional MDR reversal agents verapamil (VRP), under 1 μ mol/L concentration, still have stronger reverse activity.Because 2,4,5-tri-substituted imidazoles itself is similar to the cytotoxicity of MDR cell and corresponding sensitive strain thereof, prompting 2,4, the 5-tri-substituted imidazoles may not have influence to cancer therapy drug metabolism power.Therefore, 2,4, the 5-tri-substituted imidazoles has the prospect that exploitation becomes the newtype drug of MDR reversal agents.
Therefore, of the present invention 2,4, the 5-tri-substituted imidazoles, especially wherein phenyl 2-[(4-methyl-anti--acrylate)]-4,5-two-(4-N, N-isopropyl methyl-aminophenyl)-1 (H)-imidazoles (compound 12, FG020326), 2-[(4-methyl-anti--acrylate) phenyl]-4,5-two-(4-N, N-diethylamino phenyl)-1 (H)-imidazoles (compound 16, FG020327) or 2-[4-(2-pyridine-2-base-vinyl) phenyl]-4,5-two-(4-N, N-diethylamino phenyl)-1 (H)-imidazoles (compound 17, FG020718), can be used for preparing the multidrug resistance that is used for the reversing tumor cell, recover the medicine of MDR tumour cell cancer therapy drug susceptibility; Be used to reverse multidrug resistance especially for preparation, recover the medicine of MDR tumour cell cancer therapy drug susceptibility by P-glycoprotein, MRP or these protein called membrane transporters tumour cells that family mediates of lung MRP.
Embodiment
The present invention is described further by the following examples.
Embodiment one: 1-(right-the formyl radical phenyl)-anti--methyl acrylate (compound 1) synthetic
With 0.07g (0.3mmol) Pd (OAc) 2, 0.37g (1.22mmol) PPh 3Place 60ml DMF, add 5g (27mmol) p-bromobenzaldehyde, 2.32g (27mmol) methyl acrylate, behind 100 ℃ of reaction 14h, column chromatography for separation obtains white solid product 1, heavy 4.80g, and 82.5 ℃ of fusing points, productive rate are 93.47%. 1H-NMR (500MHz, CDCl 3): δ 3.83 (S, 3H), 6.56 (d, 1H), 7.67 (m, 2H), 7.72 (d, 1H), 7.90 (m, 2H), 10.04 (S, 1H); MS (FAB) is (m/z): 191 (base peak, M+H), 159 (M-OCH 3), 131 (M-COOCH 3), 105 (M-CH=CHCO 2CH 3).
Compound 1
Embodiment two: 1-(right-ethylene glycol contract formyl radical phenyl)-anti--methyl acrylate (compound 2) synthetic
1.90g (10mmol) 1 is dissolved in the 60ml benzene, adds 1.50g (24.2mmol) ethylene glycol, load onto water trap, back flow reaction 3h, be chilled to room temperature after, add ethyl acetate 20ml, use saturated NaHCO successively 3, NaCl solution wash (each 2 * 20ml), use anhydrous Na 2SO 4Drying, steam behind the solvent a faint yellow solid, column chromatography for separation obtains white solid product 2, heavy 2.25g, productive rate is 96.15%. 1H-NMR (500MHz, CDCl 3): δ 3.81 (S, 3H), 4.09 (m, 4H), 5.83 (s, 1H), 6.46 (d, 1H), 7.53 (m, 4H), 7.70 (d, 1H); MS (FAB) is (m/z): 235 (M+H), 203 (M-OCH 3), 175 (M-COOCH 3), 149 (base peak, M-CH=CHCO 2CH 3).
Compound 2
Embodiment three: 1-(right-ethylene glycol contract formyl radical phenyl)-anti--vinylcarbinol (compound 3) synthetic
At room temperature, to absolute anhydrous diethyl ether of 30ml and 0.4gLiAlH 4Slowly splash into the absolute anhydrous ether solution of 30ml that is dissolved with 2.34g (10mmol) 2 in the suspension that (10.54mmol) blendes together, dripped off in about 20 minutes.Restir 60 minutes, the NaOH aqueous solution 10ml of adding 1M stirred after 20 minutes, standing demix, the ether layer is washed with saturated NaCl solution, uses anhydrous Na 2SO 4Drying, steam behind the solvent a faint yellow thick liquid, column chromatography for separation obtains white solid product 3, heavy 1.65g, productive rate is 80.10%. 1H-NMR (500MHz, CDCl 3): δ 2.81 (br, 1H), 4.09 (m, 4H), 4.23 (dd, 2H), 5.76 (s, 1H), 6.32 (dt, 1H), 6.55 (d, 1H), 7.37 (m, 4H); MS (FAB) is (m/z): 207 (M+H), 189 (M-OH), 149 (M-CH=CHCH 2OH), 73 (base peaks).
Figure C0214975200093
Compound 3
Embodiment four: right-ethylene glycol contracts synthesizing of formyl radical phenyl-anti--chlorallylene (compound 4)
3.1g (15mmol) 3 is dissolved among the 50ml DCM, adds 5g (19mmol) Ph 3P, 6g (39mmol) CCl 4, behind the room temperature reaction 3h, add saturated NaHCO 3Aqueous solution 20ml stirs, and solution becomes pink, continues to stir 20 minutes, and solution becomes greenish orange look, and standing demix, water layer with 20ml DCM extraction, merge organic layer again, wash (10ml * 1) with the saturated NaCl aqueous solution, use anhydrous Na 2SO 4Drying steams solvent, gets an oily matter, and column chromatography for separation obtains white solid product 4, heavy 2.90g, and productive rate is 86.13%.
Compound 4
Embodiment five: 4-(3-N, N-diethylin-anti--1-propenyl)-phenyl aldehyde (compound 5) synthetic
0.786g (3.5mmol) 4 is dissolved in 40mlCH 3Among the CN, add 1.6g (21.9mmol) diethylamine, the stirring at room reaction, reaction solution becomes orange redly by faint yellow, react after 2 days, the basic disappearance of raw material point, adding 1N HCl 30ml, stirring at room 1h adds saturated Na again 2CO 3Solution stirs 30min to alkalescence, adds ethyl acetate 60ml, tells organic layer, and water layer is used ethyl acetate extraction (20ml * 3) again, merges organic layer, uses anhydrous Na 2SO 4Drying steams solvent, gets an orange, and column chromatography for separation obtains orange-yellow oily thing 5, heavy 0.63g, and productive rate is 82.94%. 1H-NMR (500MHz, CDCl 3): δ 1.09 (t, 6H), 2.61 (q, 4H), 3.31 (d, 2H), 6.50 (dt, 1H), 6.60 (d, 1H), 7.52 (m, 2H), 7.83 (m, 2H), 9.98 (s, 1H); MS (FAB) is (m/z): 218 (M+H), 216 (M-H), 202 (M-CH 3), 18g (M-C 2H 5Or-HCO), 117 (base peaks), 86.
Figure C0214975200102
Compound 5
Embodiment six: 4-(3-N, N-methylethyl amino-anti--1-propenyl)-phenyl aldehyde (compound 6) synthetic
By the same method of embodiment five by 4 and the reaction of methylethyl amine make, productive rate is 77.41%. 1H-NMR (500MHz, CDCl 3): δ 1.13 (t, 3H), 2.29 (s, 3H), 2.51 (q, 2H), 3.22 (d, 2H), 6.47 (dt, 1H), 6.59 (d, 1H), 7.52 (m, 2H), 7.83 (m, 2H), 9.97 (s, 1H); MS (FAB) is (m/z): 204 (M+H), 202 (M-H), 188 (M-CH 3), 174 (M-C 2H 5Or-HCO), 145,117 (base peaks), 72.
Figure C0214975200103
Compound 6
Embodiment seven: 3-indolecarboxaldehyde (compound 7) synthetic
Add 29.24g (0.4mol) DMF in a 250ml there-necked flask, fully cooling splashes into 15.34g (0.1mol) POCl in about 0.5 hour under the mechanical stirring in cryosel is bathed 3Obtain pink solution, maintain the temperature at and splash into the solution that 10.54g (0.09mol) indoles is dissolved in 15mlDMF below 10 ℃, dripped off in about 1 hour, obtain a viscous mixture, be warming up to 35 ℃ of stirring reactions 1 hour, and got an opaque mashed prod, color becomes orange-yellow, and there is yellow solid to separate out, under the ice bath cooling, slowly add the 30g trash ice, stirred 10 minutes, get a pink solution.
In a beaker, add the 20g trash ice, above-mentioned solution is poured into, under stirring 40g (1mol) NaOH is dissolved in 100mlH 2The cold soln of O slowly adds, and solid product is leached, and is washed to nearly neutrality, uses ethyl alcohol recrystallization, gets light yellow solid product 7, heavy 11.7g, and fusing point: 196～197 ℃, productive rate is 89.59%. 1H-NMR(500MHz，CD 3OD)：δ9.88(s，1H)，8.15(d，1H)，8.06(s，1H)，7.46(d，1H)，7.28～7.21(m，3H)；MS(FAB)(m/z)：146(M+H)。
Compound 7
Embodiment eight: 2-(right-formyl radical) stibazole (compound 8) synthetic
With 6.7g (50mmol) terephthalaldehyde, 4.67g (50mmol) 2-picoline, 5.52g (54mmol) aceticanhydride reflux together 4 hours, dark red solution, be neutralized to PH with 1MNaOH solution and be about 8, use CH 2Cl 2Extraction (50ml * 3) merges organic layer, uses anhydrous Na 2SO 4Drying steams solvent, gets a yellow solid, and column chromatography for separation obtains light yellow solid product 8, heavy 5.2g, and fusing point: 84～86 ℃, productive rate is 62.13%. 1H-NMR(500MHz，CD 3OD)：δ9.98(s，1H)，8.54(d，1H)，7.92(d，2H)，7.82(m，1H)，7.79(d，2H)，7.66(d，1H)，7.65(m，1H)，7.40(d，1H)，7.29(dd，1H)；MS(FAB)(m/z)：210(M+H)。
Figure C0214975200112
Compound 8
Embodiment nine: 4,4 '-N, the amino benzil of N-isopropyl methyl (compound 9) synthetic
With 0.82g (3.33mmol) 4,4 '-difluoro benzil is dissolved in (0.5M) among the 7ml DMSO, add 0.49g (6.7mmol) isopropyl methyl amine, in 90 ℃ of following reacting by heating of oil bath, reaction solution is become orange by yellow, stopped reaction behind the 15h, steam solvent, column chromatography for separation obtains orange solids 9, heavy 1.05g, and productive rate is 89.52%. 1H-NMR (500MHz, CDCl 3): δ 1.22 (d, 12H), 2.84 (s, 6H), 4.21 (7,2H), 6.73 (d, 4H), 7.84 (d, 4H); MS (FAB) is (m/z): 353 (M+H), 176 (base peaks).
Compound 9
Embodiment ten: 4,4 '-N, N-diethylamino benzil (compound 10) synthetic
Press the same method of embodiment nine by 4,4 '-difluoro benzil and diethylamine reaction make, and productive rate is 93.59%. 1H-NMR (500MHz, CDCl 3): δ 1.20 (t, 12H), 3.42 (q, 8H), 6.63 (d, 4H), 7.83 (d, 4H); MS (FAB) is (m/z): 353 (M+H), 176 (base peaks).
Compound 10
Embodiment 11: 2-[4-(3-N, N-methylethyl amino-anti--1-propylene-1-yl) phenyl]-4,5-two-(4-N, N-isopropyl methyl-aminophenyl)-1 (H)-imidazoles (compound 11) synthetic
In a flask, 0.51g (2.5mmol) 6 and 0.71g (2mmol) 9 are dissolved in the 10ml Glacial acetic acid, are heated to 140 ℃, in another flask with 0.8g (10.5mmol) NH 4OAc places the 3ml Glacial acetic acid, also is heated to 140 ℃, after the solid for the treatment of both sides all dissolves fully, with NH 4The glacial acetic acid solution of OAc is poured in another flask, and 140 ℃ of reaction 2h steam solvent, get a sorrel solid, and column chromatography for separation obtains orange solids 11, heavy 0.92g, and productive rate is 85.98%. 1H-NMR (500MHz, CDCl 3): δ 1.18 (m, 15H), 2.33 (s, 3H), 2.55 (q, 2H), 2.80 (s, 6H), 3.27 (m, 2H), 3.57 (br.s, 2H), 6.37 (dt, 1H), 6.57 (d, 1H), 6.73 (d, 4H), 7.44 (m, 6H), 7.84 (m, 2H); MS (FAB) is (m/z): 536 (M+H), 535 (base peak, M), 477 (McLafferty rearrangement, M-N (CH 3) CH 2CH 3), 463 (M-CH 2N (CH 3) CH 2CH 3).
Compound 11
Embodiment 12: phenyl 2-[(4-methyl-anti--acrylate)]-4,5-two-(4-N, N-isopropyl methyl-aminophenyl)-1 (H)-imidazoles (compound 12, FG020326) synthetic
Made by 1 and 9 reactions by embodiment 11 same methods, productive rate is 91.73%. 1H-NMR (500MHz, CDCl 3): δ 1.18 (d, 12H), 2.81 (s, 6H), 3.28 (m, 2H), 3.76 (s, 3H), 6.40 (d, 1H), 6.71 (d, 4H), 7.45 (m, 6H), 7.62 (d, 1H), 7.85 (m, 2H); MS (FAB) is (m/z): 523 (base peak, M+H), 507 (M-CH 3), 491 (M-OCH 3), 479 (M-CH (CH 3) 2), 463 (M-CO 2CH 3).
Figure C0214975200123
Compound 12 (FG020326)
Embodiment 13: 2-[4-(3-N, N-diethylamino-anti--1-propylene-1-yl) phenyl]-4,5-two-(4-N, N-isopropyl methyl-aminophenyl)-1 (H)-imidazoles (compound 13) synthetic
Made by 5 and 9 reactions by embodiment 11 same methods, productive rate is 86.55%. 1H-NMR (500MHz, CDCl 3): δ 1.15～1.18 (m, 18H), 2.53 (q, 4H), 2.81 (s, 6H), 3.28 (m, 2H), 3.62 (br.s, 2H), 6.38 (m, 1H), 6.59 (d, 1H), 6.71 (d, 4H), 7.40～7.44 (m, 6H), 7.83 (m, 2H); MS (FAB) is (m/z): 550 (M+H), 549 (M), 520 (M-CH 2CH 3), 477 (base peak, McLafferty rearrangement, M-N (CH 2CH 3) 2), 463 (M-CH 2N (CH 2CH 3) 2).
Compound 13
Embodiment 14: 2-(4-pyridyl)-4,5-two-(4-N, N-diethylamino phenyl)-1 (H)-imidazoles (compound 14) synthetic
Made by 4-pyridylaldehyde and 10 reactions by embodiment 11 same methods, productive rate is 68.24%. 1H-NMR(500MHz，CDCl 3)：δ1.12(t，12H)，3.32(q，8H)，6.74(d，4H)，7.45(d，4H)，7.78(d，2H)，8.68(d，2H)；MS(FAB)(m/z)：440(M+H)。
Figure C0214975200132
Compound 14
Embodiment 15: 2-(3-indyl)-4,5-two-(4-N, N-diethylamino phenyl)-1 (H)-imidazoles (compound 15) synthetic
Made by 7 and 10 reactions by embodiment 11 same methods, productive rate is 75.37%. 1H-NMR(500MHz，CDCl 3)：δ1.11(t，12H)，3.32(q，8H)，6.74(d，4H)，7.25～7.40(m，3H)，7.45(d，4H)，7.68(s，1H)，7.84(d，1H)；MS(FAB)(m/z)：478(M+H)。
Compound 15
Embodiment 16: phenyl 2-[(4-methyl-anti--acrylate)]-4,5-two-(4-N, N-diethylamino phenyl)-1 (H)-imidazoles (compound 16, FG020327) synthetic
Made by 1 and 10 reactions by embodiment 11 same methods, productive rate is 89.48%. 1H-NMR(500MHz，CDCl 3)：δ1.12(t，12H)，3.32(q，8H)，3.76(s，3H)，6.40(d，1H)，6.72(d，4H)，7.45(m，6H)，7.61(d，1H)，7.84(d，2H)；MS(FAB)(m/z)：523(M+H)。
Figure C0214975200141
Compound 16 (FG020327)
Embodiment 17: 2-[4-(2-pyridine-2-base-vinyl) phenyl]-4,5-two-(4-N, N-diethylamino phenyl)-1 (H)-imidazoles (compound 17, FG020718) synthetic
Made by 8 and 10 reactions by embodiment 11 same methods, productive rate is 75.37%. 1H-NMR(500MHz，CDCl 3)：δ1.13(t，12H)，334(q，8H)，6.70(d，4H)，7.35(m，1H)，7.42～7.71(m，12H)，8.64(d，1H)；MS(FAB)(m/z)：542(M+H)。
Figure C0214975200142
Compound 17 (FG020718)
Embodiment 18: formula I compound is used for the reversing tumor multidrug resistance
With two pair cell strains, MDR cell KBv200 and MCF-7/adr and corresponding sensitive strain KB and MCF-7, mtt assay carries out cell toxicant to be measured, and the logarithmic phase cell adds the thing that tried of different concns, acts on after 72 hours, measures its absorbancy.Calculate the drug level that cell growth inhibiting reaches at 50% o'clock respectively, with IC 50Value representation.The reverse multiple is IC 50 (ADR)/ IC 50 (ADR+ reversal agent)Carry out reversion MDR research in the body with the transplanted tumor in nude mice model, the result is as shown in table 1.The result shows that compound 12 (FG020326), compound 16 (FG020327) or compound 17 (FG020718) have stronger inside and outside reversion MDR activity; Under the concentration of 5 μ mol/L, almost completely reverse the resistance of KBv200 cell to vincristine(VCR) (VCR); 0.625 still have 11.76,5.32 and 3.60 times reversion MDR activity under the concentration of μ mol/L respectively.Owing to itself MDR cell and corresponding sensitive cells are had similar cytotoxicity, prompting is not the substrate of P-gp.
The effect of table 1.FG020327 and homologue reversion MDR thereof
Reversal agent and concentration MDR reverses multiple Reversal agent and concentration MDR reverses multiple
KBv200 to VCR MCF-7/adr to Dox KBv200 to VCR MCF-7/adr to Dox
Compound 11 0.625 μ M 1.25 μ M 2.5 μ M 1.78 2.69 3.85 1.09 3.29 6.42 Compound 15 0.625 μ M 1.25 μ M 2.5 μ M 5.0 μ M 0.94 3.14 17.26 / 1.14 1.63 7.39 7.90
Compound 12 (FG020326) 0.625 μ M 1.25 μ M 2.5 μ M 5.0 μ M 10.0 μ M 11.76 20.36 38.57 53.93 73.52 2.43 10.91 10.88 13.85 18.51 Compound 16 (FG020327) 0.625 μ M 1.25 μ M 2.5 μ M 5.0 μ M 10.0 μ M 5.32 22.46 39.37 44.32 61.72 2.11 4.69 5.15 5.57 6.16
Compound 13 0.625 μ M 1.25 μ M 2.5 μ M 5.0 μ M 1.68 2.72 5.60 8.91 1.92 4.22 4.81 15.96 Compound 17 (FG020718) 0.625 μ M 1.25 μ M 2.5 μ M 5.0 μ M 10 μ M 3.60 22.35 34.85 44.13 46.91 1.96 2.64 6.18 7.13 8.04
Compound 14 0.625 μ M 1.25 μ M 2.5 μ M 5.0 μ M 1.36 8.18 11.36 81.25 2.20 2.48 4.53 4.33
Annotate: the KBv200 cell to vincristine(VCR) (VCR) than 90 times of its corresponding sensitive strain KB resistances;
The MCF-7/adr cell to Zorubicin (Dox) than 45 times of its corresponding sensitive strain MCF-7 resistances
Above test-results shows of the present invention 2,4, the 5-tri-substituted imidazoles, especially compound 12 (FG020326), compound 16 (FG020327) and compound 17 (FG020718) have DEVELOPMENT PROSPECT, can be used for preparing the newtype drug of MDR reversal agents.Drug prepared can be used as MDR reversal agents, is used to increase the susceptibility of chemotherapy; This medicine and traditional chemotherapeutics share, and can delay and prevent the generation of MDR.

Claims (7)

1. 2,4 shown in the formula I, the 5-tri-substituted imidazoles:
Formula I
R among the formula I 1, R 2, R 3The group of representative is as described in the and the following:
(1) R 1Be the phenyl that replaces, said here substituting group is trans-CH=CHR 4, R wherein 4Be the 2-pyridyl;
(2) R 2, R 3Can be identical, also can be different, be the phenyl that replaces, said here substituting group is C 1-6Alkylamino or C 1-6Dialkyl amido.
2. the preparation method of the described formula I compound of claim 1, concrete steps are: 1 normal diketone and 1～1.5 normal aldehyde are placed Glacial acetic acid, be heated to 140 ± 5 ℃; In addition with 3～5 normal NH 4OAc places Glacial acetic acid, also is heated to 140 ± 5 ℃; After the solid for the treatment of both sides all dissolves fully, with NH 4The glacial acetic acid solution of OAc adds in the glacial acetic acid solution of diketone and aldehyde, 140 ± 5 ℃ of reaction 1～2h; Steam solvent, promptly obtain corresponding polyaryl substituted imidazole compound through column chromatographic isolation and purification then; Reaction process and used diketone thereof and aldehyde are suc as formula shown in the II:
Formula II
3. in accordance with the method for claim 2, it is characterized in that used diketone makes by the following method: with 1 normal 4,4 '-difluoro benzil is dissolved among the DMSO, add 2～3 equivalents and replace amine, at 70～90 ℃ of following reacting by heating 10～15h of oil bath, steam solvent, column chromatographic isolation and purification obtains corresponding diketone.
4. in accordance with the method for claim 2, it is characterized in that used aldehyde is to make by the following method:
With terephthalaldehyde, 2-picoline, aceticanhydride reflux together 3～5 hours, being neutralized to pH with 1MNaOH solution was 8～9, uses CH 2Cl 2Extraction merges organic layer, uses anhydrous Na 2SO 4Drying steams solvent after column chromatographic isolation and purification obtains 2-(right-formyl radical) stibazole.
5. the described formula I compound of claim 1 is used for the multidrug resistance (MDR) of reversing tumor cell in preparation, recovers tumour cell to the application in the medicine of cancer therapy drug susceptibility.
6. according to the described application of claim 5, it is characterized in that said medicine is the multidrug resistance (MDR) that is used to reverse by P-glycoprotein, MRP or these protein called membrane transporters tumour cells that family mediates of lung MRP, recover the medicine of tumour cell cancer therapy drug susceptibility.
7. according to claim 5 or 6 described application, it is characterized in that said formula I compound is 2-[4-(2-pyridine-2-base-vinyl) phenyl]-4,5-two-(4-N, N-diethylamino phenyl)-1 (H)-imidazoles.
CNB021497524A 2002-12-27 2002-12-27 2,4,5-trisubstituted imidazole compounds and its preparing process and pharmaceutical use Expired - Fee Related CN1181061C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB021497524A CN1181061C (en) 2002-12-27 2002-12-27 2,4,5-trisubstituted imidazole compounds and its preparing process and pharmaceutical use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB021497524A CN1181061C (en) 2002-12-27 2002-12-27 2,4,5-trisubstituted imidazole compounds and its preparing process and pharmaceutical use

Publications (2)

Publication Number Publication Date
CN1425653A CN1425653A (en) 2003-06-25
CN1181061C true CN1181061C (en) 2004-12-22

Family

ID=4751743

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB021497524A Expired - Fee Related CN1181061C (en) 2002-12-27 2002-12-27 2,4,5-trisubstituted imidazole compounds and its preparing process and pharmaceutical use

Country Status (1)

Country Link
CN (1) CN1181061C (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2900404B1 (en) * 2006-04-27 2008-07-18 Sod Conseils Rech Applic NOVEL IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS A MEDICINAL PRODUCT
CN101812020B (en) * 2010-05-05 2011-11-23 扬州大学 Synthesis method of tetra-substituted imidazole medicament molecule and analogs thereof
CN101805295A (en) * 2010-05-05 2010-08-18 扬州大学 Method for synthesizing trisubstituted imidazole medicament molecules and analogue thereof
CN103880755B (en) * 2014-03-24 2015-07-01 安徽工业大学 Method for preparing 2,4,5-triaryl substituted imidazole through catalysis of degradable acidic ionic liquid
CN104151301B (en) * 2014-07-10 2016-08-17 中山大学 A kind of fluorescent probe and its preparation method and application
CN104710977B (en) * 2015-01-23 2016-08-24 中山大学 A kind of double function probe and preparation method thereof and the application in detecting positive parallel conformation G-tetra-serobila
CN109535079B (en) * 2019-01-04 2022-04-19 陇东学院 Preparation method of 2,4, 5-trisubstituted imidazole
CN110028671B (en) * 2019-04-23 2021-06-01 湘潭大学 Benzimidazole-linked triphenyl imidazole polymer and preparation method and application thereof

Also Published As

Publication number Publication date
CN1425653A (en) 2003-06-25

Similar Documents

Publication Publication Date Title
CN1075811C (en) Novel substituted 2,4-thiazolidine diketone derivatives, method for preparation thereof and pharmaceutical compositions containing the same
CN1391573A (en) Bicyclic imidazo-3-yl-amine derivatives
CN1036779C (en) Cryogenic rectification system with argon heat pump
CN1181061C (en) 2,4,5-trisubstituted imidazole compounds and its preparing process and pharmaceutical use
CN1150197C (en) Naphtho- and dihydrobenzo-thiopyhene derivatives as cytotoxic antitumor agents
CN1142227A (en) Novel thiazolidin-4-one derivatives
CN1090633C (en) Chlorophyll alpha degraded product metal complex, its preparation method and medicament for anti-gastric ulcer
CN1455766A (en) Novel 1,2-diphenylethene derivatives for treatment of immune diseases
CN1736986A (en) Polyhydroxy stilbenes compound preparation and uses as drugs for suppressing SARS
CN1019010B (en) Process for preparing substituted beta-diketones
CN1148362C (en) Polycyclic 2-aimino-thiazole systems, method for prodn. thereof and medicament contg. said compounds
CN1847240A (en) Prazole derivative and its salt and use
CN1313766A (en) DNA-cleaving antitumor agents
CN1141940C (en) Use of polycyclic thiazole systems for producing medicaments for preventing of treating obesity
CN85105193A (en) Preparation benzothiophene anti-diarrhoeal agents method
CN1042935C (en) Chemical compounds
CN1109544C (en) Beta-alkoxyacrylates against malaria
CN1054123C (en) Carbamic acid derivatives and method for preparing same
CN1162152C (en) Remedies for diabetes
CN1149205C (en) Polycyclic thiazole systems and their utilization as anorectics
CN1177843C (en) Novel chalcones
CN100349884C (en) 3-phenylfuran-2-one derivatives as cox-2 inhibitor
CN1775762A (en) Liyustrazine acyl piperazine derivative, and its preparing method and medicinal composition and use
CN1445217A (en) Substitutional ramification of tetrahydro-isoquinoline, as well as its preparing method and its medication compound containing them
CN1211088C (en) Application of emodin analog EMD-31 for curing tumor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20041222

Termination date: 20131227